{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-082089","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.701026+00:00","generated_at":"2026-05-23T13:31:56.098912+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025","bullets":["Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.","Received option for 35,000 shares and 21,000 RSUs, both vesting over three years; plus cash compensation.","Former CEO of Nabriva Therapeutics, co-founded Cadence Pharmaceuticals (bought by Mallinckrodt), held senior roles at Elan, Dura, and Bristol-Myers Squibb.","Board determined Schroeder meets Nasdaq independence standards; no related party transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-082089","json":"https://secwatch.observer/filing/0001193125-25-082089.json","markdown":"https://secwatch.observer/filing/0001193125-25-082089.md","text":"https://secwatch.observer/filing/0001193125-25-082089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/0001193125-25-082089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/d943974d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T13:31:56.098912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b747951331","claim":"Theodore R. Schroeder was appointed as Director at Phathom Pharmaceuticals, Inc..","evidence_excerpt":"The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/0001193125-25-082089-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}